Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

OBJECTIVE: To compare the effectiveness of meropenem with imipenem plus cilastatin in the treatment of severe infections. DATA SOURCES: CENTRAL, EMBASE and MEDLINE were searched for abstracts and papers. All searching was completed in March 2004. No restriction was placed on language. STUDY SELECTI...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Edwards, S, Emmas, C, Campbell, H
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2005

Míreanna comhchosúla

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
de réir: Edwards, S, et al.
Foilsithe / Cruthaithe: (2006)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
de réir: Xi You, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
de réir: Eman Youssif, et al.
Foilsithe / Cruthaithe: (2018-07-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
de réir: Pasquale Sansone, et al.
Foilsithe / Cruthaithe: (2024-05-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
de réir: Hiroki Nakamura, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Effect of Oxygen and Water on the Stability of Imipenem and Cilastatin Sodium for Injection
de réir: Meng Zhang, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
de réir: Alex A. Erasmo
Foilsithe / Cruthaithe: (2004-07-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
de réir: Maria Agudelo, et al.
Foilsithe / Cruthaithe: (2019-01-01)

The Pattern of Imipenem/Cilastatin Administration in Imam Khomeini Hospital (Ardabil) in 2018
de réir: Moien Zakavati, et al.
Foilsithe / Cruthaithe: (2019-04-01)

Corrigendum to “Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients” [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]
de réir: Xi You, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
de réir: Ryan K. Shields, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
de réir: Takahiro Arima, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
de réir: Mona I. Shaaban, et al.
Foilsithe / Cruthaithe: (2017-04-01)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
de réir: Kabbara WK, et al.
Foilsithe / Cruthaithe: (2015-03-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
de réir: Paul Laffont-Lozes, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
de réir: Jaesh Naik, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
de réir: Yanna Zhu, et al.
Foilsithe / Cruthaithe: (2020-03-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
de réir: Lionel A Mandell, et al.
Foilsithe / Cruthaithe: (1993-01-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
de réir: Shakila Baei Lashaki, et al.
Foilsithe / Cruthaithe: (2025-05-01)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
de réir: Islam M Ghazi, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
de réir: Chang-Hua Chen, et al.

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
de réir: Faezeh Milani, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
de réir: Takaki Hirano, et al.
Foilsithe / Cruthaithe: (2022-12-01)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
de réir: Xiaokui Huo, et al.
Foilsithe / Cruthaithe: (2019-09-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
de réir: I. I. Shteynberg, et al.
Foilsithe / Cruthaithe: (2015-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
de réir: C Kani, et al.
Foilsithe / Cruthaithe: (2005-06-01)

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
de réir: Chen Xiaoping, et al.
Foilsithe / Cruthaithe: (2010-07-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
de réir: Sakiko Hiraki, MD, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
de réir: E. Dahdouh, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa
de réir: Glenn J. Rapsinski, et al.
Foilsithe / Cruthaithe: (2025-03-01)

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report
de réir: A. B. Strok, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
de réir: A. K. Chaudhary, et al.
Foilsithe / Cruthaithe: (2010-01-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
de réir: Telma de Sousa, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
de réir: Sakiko Hiraki, et al.
Foilsithe / Cruthaithe: (2023-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
de réir: Kani C., et al.
Foilsithe / Cruthaithe: (2005-07-01)

Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
de réir: George G Zhanel, et al.
Foilsithe / Cruthaithe: (1998-01-01)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
de réir: Hassuna NA, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
de réir: Peng Jia, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
de réir: Qingxin Yang, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
de réir: Hazhir Moradi, et al.
Foilsithe / Cruthaithe: (2024-12-01)